Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects

Clin Infect Dis. 2005 May 1;40(9):1358-61. doi: 10.1086/429327. Epub 2005 Mar 31.

Abstract

We examined 516G>T polymorphisms at the gene encoding the cytochrome P450 in 100 human immunodeficiency virus-positive subjects who were receiving efavirenz (EFV). Elevated plasma EFV concentrations were found in 40% of subjects with the polymorphic homozygous genotype and 19% of subjects with the heterozygous genotype. Conversely, 20% of subjects with the wild-type genotype had subtherapeutic concentrations of EFV. CYP2B6-516 genotyping may help to identify subjects who have plasma EFV concentrations that are outside of the therapeutic range.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Alkynes
  • Benzoxazines
  • Cyclopropanes
  • Cytochrome P-450 Enzyme System / genetics*
  • Female
  • Genotype
  • HIV Infections / blood
  • HIV Infections / drug therapy*
  • HIV Infections / genetics*
  • Heterozygote
  • Homozygote
  • Humans
  • Isoenzymes / genetics
  • Male
  • Middle Aged
  • Oxazines / adverse effects
  • Oxazines / blood*
  • Oxazines / pharmacokinetics*
  • Polymorphism, Single Nucleotide*

Substances

  • Alkynes
  • Benzoxazines
  • Cyclopropanes
  • Isoenzymes
  • Oxazines
  • Cytochrome P-450 Enzyme System
  • efavirenz